Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287660 | 0.96 | HRH3 (0.68) | HRH3KMT2AACHERAD52 | |
| SCHEMBL14287678 | 0.96 | HRH3 (0.68) | HRH3KMT2AACHERAD52 | |
| SCHEMBL14287674 | 0.90 | HRH3 (0.68) | HRH3ACHERAD52 | |
| SCHEMBL5100294 | 0.89 | KMT2A (0.59) | HRH3KMT2AATML3MBTL1ACHE | |
| SCHEMBL5097548 | 0.89 | HRH3 (0.71) | HRH3KMT2AACHERAD52 | |
| Hydrochloric Acid SCHEMBL5100664 | 0.87 | HRH3 (0.70) | HRH3KMT2AACHERAD52 | |
| SCHEMBL14287677 | 0.85 | HRH3 (0.66) | HRH3ACHERAD52 | |
| SCHEMBL14287710 | 0.84 | HRH3 (0.70) | HRH3ACHERAD52 | |
| SCHEMBL14287663 | 0.84 | HRH3 (0.68) | HRH3KMT2A | |
| SCHEMBL3175086 | 0.84 | DPP7 (0.70) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314937-B2 | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885KMT2A 113/4885ATM 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.